%0 Journal Article
%T Sacubitril/valsartan: An antiarrhythmic drug?
%A Huang E
%A Bernard ML
%A Elise Hiltbold A
%A Khatib S
%A Polin GM
%A Rogers PA
%A Dominic P
%A Morin DP
%J J Cardiovasc Electrophysiol
%V 0
%N 0
%D Sep 2022 7
%M 36069136
%F 2.942
%R 10.1111/jce.15670
%X <B>BACKGROUND: </B>Heart failure (HF) is a major cause of morbidity and mortality, with nearly half of all HF-related deaths resulting from sudden cardiac death (SCD), most often from an arrhythmic event. The pathophysiologic changes that occur in response to the hemodynamic stress of HF may lead to increased arrhythmogenesis. Theoretically, medications that block these arrhythmogenic substrates would decrease the risk of SCD. The combined angiotensin receptor and neprilysin inhibitor (ARNi; tradename Entresto) is the newest commercially available medication for the treatment of heart failure.<BR><B>RESULTS: </B>We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac rhythm. ARNi has been shown to decrease cardiovascular mortality and hospitalization in patients with HF with reduced ejection fraction (HFrEF). Emerging evidence suggests that ARNi also may play a role in reducing arrhythmogenesis and thereby SCD.<BR><B>CONCLUSIONS: </B>This review summarizes the current data regarding this ARNi and its potential antiarrhythmic effects.